Thulium Laser Enucleation of The Prostate for Treatment of Benign Prostatic Hyperplasia: A Single Center Experience

Document Type : Original Article

Authors

1 Department of Urology, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt

2 Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

3 Department of Urology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

Abstract

Background: Benign prostatic hyperplasia [BPH] is a prevalent medical condition in older men that leads to symptoms affecting the lower urinary system [LUTS]. Thulium Laser Enucleation of The Prostate [THULEP] seems to be a promising procedure for treatment of BPH with minimal side effects.
Aim of the work: The aim of this study was to evaluate the outcomes of THULEP in patients with benign prostatic hyperplasia.
Patients and methods: A prospective non-controlled study included 30 participants who have failed medical therapy to LUTS attributable to BPH and underwent THULEP. The primary outcome was international prostate symptom scores [IPSS] score at 6 months. Other outcomes included operative time, intraoperative complications, length of hospital stay, changes in the maximum flow rate, post voiding residual [PVR], prostate-specific antigen [PSA] and continence status.
Results: The mean [range] prostate size was 72.3 [40-124] ml, the mean operative duration was 86.40 [48-123] min and the mean enucleation time 73.33 [40-105] min. The improvements in IPSS, Qmax, PVR and PSA were significant [P < 0.001], with mean values before and after THULEP [IPSS from 25 to 2.5, Qmax from 10 ml/sec to 18.1 ml/sec, PVR from 92.5 to 13 ml, PSA from 3 to 1.05, respectively]. Of the 30 patients, 20 [66.6%] were catheter-free on the first day after THULEP; the mean hospital stay was 2.63 days.
Conclusion: The BPH can be completely removed with ThuLEP. The methods combine high effectiveness with negligible negative effects.

Keywords

Main Subjects

Files

Share

How to cite

Statistics